Physician profile
Ignacio Guzman
NPI 1770895724
$4,502.47
in general payments reported to CMS, 2019-2025
30 companies · $179 in 2025
The $179 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $833 · 2020: $1,104 · 2021: $1,373 · 2022: $728 · 2023: $86.51 · 2024: $200 · 2025: $179.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $465.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $696.49 | 2019-2025 | Farxiga, Breztri |
| Lilly USA, LLC | $587.10 | 2019-2022 | |
| Novo Nordisk INC | $552.57 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $475.59 | 2019-2022 | |
| Amarin Pharma, INC. | $439.18 | 2019-2023 | |
| Abbvie INC. | $353.22 | 2020-2023 | |
| Novartis Pharmaceuticals Corporation | $209.66 | 2019-2022 | |
| Allergan, INC. | $173.21 | 2020 | |
| Glaxosmithkline, LLC. | $140.15 | 2019-2022 | |
| Madrigal Pharmaceuticals | $123.86 | 2024 | Rezdiffra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.88 | 2020-2022 | |
| Merck Sharp & Dohme LLC | $105.23 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $101.21 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.31 | 2021-2022 | |
| Horizon Therapeutics Plc | $54.85 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $42.12 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $37.15 | 2022 | |
| Tosoh Bioscience, INC. | $24.29 | 2025 | |
| Gilead Sciences, INC. | $21.67 | 2020 | |
| Dexcom, INC. | $18.30 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.01 | 2022 | |
| Vertiflex, INC. | $16.40 | 2019 | |
| Redhill Biopharma INC. | $16.39 | 2020 | |
| Idorsia Pharmaceuticals US INC | $16.37 | 2023 | Quviviq |
| Nestle Healthcare Nutrition INC. | $15.84 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.82 | 2025 | Xifaxan |
| Amgen INC. | $14.56 | 2019 | |
| Depuy Synthes Sales INC. | $14.07 | 2021 | |
| Arbor Pharmaceuticals, INC. | $12.26 | 2019 | |
| Galderma Laboratories, L.P. | $11.71 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ignacio Guzman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.